Figure 1.
Tysabri Observational Program (TOP) patients included in propensity score matching.
EID, extended interval dosing; Q4W, every 4 weeks; Q6W, every 6 weeks.
*Other includes infusion records with missing dates (n = 13), no Q4W infusion history (switch occurred prior to 2014; n = 5), and multiple switches between Q4W and Q6W (n = 22).